Adverum Biotechnologies Inc (ADVM.OQ)
12 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2017||Chairman of the Board|
|55||2017||Chief Executive Officer, Principal Executive Officer, Director|
|54||2016||Chief Financial Officer|
|45||2017||Senior Vice President, Chief Medical Officer|
|50||2016||Chief Science and Technology Officer|
- BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
- BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
- BRIEF-Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017
- BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share
- BRIEF-Adverum Biotechnologies says has increased size of board to eight members